Americans Skeptical of Eli Lilly Vaccine Acquisition

Executive summary

Eli Lilly's $3.8 billion bet on vaccines is drawing cautious approval from the public — but price anxiety is drowning out the optimism. A new pulse survey of 260 Americans finds that nearly half view Lilly's three-acquisition vaccine strategy as a smart diversification move, yet more than half say their gut reaction to any billion-dollar pharma deal is worry about higher drug prices.

The gap between strategic approval and emotional distrust is the central story here. Respondents can simultaneously applaud the business logic and fear the bill they'll eventually receive — a tension that Gallup and Edelman have documented at scale for years, and that this survey captures in sharp relief for Lilly's specific move.

Four takeaways stand out:

• Price fear dominates: 54.6% of respondents say higher drug prices is their first reaction to large pharma acquisitions — nearly three times the 19.6% who feel hopeful for breakthroughs.
• Strategic endorsement is real but shallow: 45.8% call Lilly's vaccine pivot a smart diversification move, but only 11.9% frame it as a good use of weight-loss drug profits — suggesting approval of the strategy, not affection for the company.
• Trust is a structural minority: Free-response data leans firmly toward the view that pharma prioritizes profit over public health, mirroring Gallup's finding that just 18% of Americans held positive views of the industry in 2023.
• The science is strong and largely invisible: Lilly's three acquired platforms address genuinely unmet needs — a better-tolerated shingles vaccine, bacterial vaccines targeting WHO-flagged AMR pathogens, and the first serious EBV vaccine candidate — but none of that clinical credibility is penetrating public perception.

Context

In May 2026, Eli Lilly announced it would acquire three vaccine developers — Curevo, LimmaTech, and Vaccine Company — for up to $3.83 billion combined, marking the company's 8th, 9th, and 10th acquisitions of the year. The rationale was direct: GLP-1 weight-loss drugs Mounjaro and Zepbound generated $19.3 billion in worldwide revenue in Q4 2025 alone, a 43% year-over-year jump. Lilly's chief scientific officer framed the pivot as an effort to "prevent disease at its source rather than treat its consequences."

The three targets are not generic vaccine plays. Curevo's amezosvatein shingles vaccine showed non-inferiority to GSK's market-dominant Shingrix in Phase 2 trials while cutting activity-limiting side effects by more than half — directly addressing the second-dose hesitancy that limits Shingrix's real-world uptake. LimmaTech is developing bacterial vaccines against pathogens — including S. aureus, gonorrhoeae, and chlamydia — that WHO flagged in a 2024 technical report as critical antimicrobial resistance priorities. Vaccine Company's IVN platform targets Epstein-Barr virus, an oncogenic pathogen linked to cancers and autoimmune diseases for which no licensed vaccine yet exists.

This pulse survey of 260 U.S. adults was fielded immediately after the announcement to capture public reaction across four dimensions: strategic assessment of the acquisition, concerns about large pharma entering vaccines, trust in pharmaceutical companies' public-health motivations, and gut-level reaction to billion-dollar pharma deals broadly. Free-response questions on trust and vaccine concerns generated 251–260 usable responses, and personality trait data was available for 58–213 respondents depending on the question, enabling correlation analysis.

The backdrop matters. Pharma trust has been depressed for years: Gallup tracked positive industry ratings falling from 31% in 2021 to 18% in 2023, with a partial rebound to roughly 40% by late 2025 driven largely by partisan shifts rather than a fundamental change in public confidence. The 2025 Edelman Trust and Health Barometer, covering 16,000 respondents across 16 countries, found that no major institution — government, business, media, or NGOs — is trusted to address health needs. That is the frame through which Americans are processing Lilly's vaccine bet.

Conclusion

Eli Lilly has a clinical story worth telling — it just hasn't broken through yet. The public is processing a $3.8 billion headline through a filter of entrenched distrust, and no amount of strategic endorsement changes the underlying reflex: when a big pharma company makes a big move, most Americans worry about the bill.

The near-term test for Lilly is whether it can make the pipeline science legible to a skeptical public before the price anxiety calcifies into opposition. That means putting amezosvatein's side-effect advantage, LimmaTech's AMR relevance, and the EBV vaccine gap in front of audiences who currently see only a corporate acquisition. It also means getting ahead of the affordability question with concrete commitments — because the pricing concern dimension data shows that fear is already present, even before any product reaches market.

Watch two signals: First, whether Lilly's communications strategy in the Phase 3 runup for Curevo explicitly addresses pricing and access alongside efficacy data. Second, whether the FTC's historically predictable review of these deals (all three major 2025 pharma deals cleared the initial 30-day window) generates any public scrutiny that reactivates the monopoly concern threading through open-end responses. The optimists are real. Reaching them requires evidence, not just announcements.